Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same author

Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer.

Frontiers in oncology·2026
Same author

Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases.

Cancers·2026
Same author

ASLNet: an explainable deep learning framework for glioma grading and survival prediction.

Frontiers in oncology·2026
Same author

Deep Eutectic Solvent-Mediated Nucleation Engineering of Bi<sub>2</sub>WO<sub>6</sub> Photocatalysts for Enhanced Visible Light Degradation of Organic Pollutants.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2025

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

11.3K

Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic.

Charles A Kunos1, Molly E Martin2, Michalis F Georgiou3

  • 1Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 1500, Miami, FL 33136, USA.

Cancers
|April 13, 2024
PubMed
Summary
This summary is machine-generated.

Radiopharmaceuticals are gaining traction for cancer treatment, enabling easier clinical trials and improved patient care. Theranostic agents are accelerating the development of these targeted radioactive drugs.

Keywords:
floor planradionuclide treatmentradiopharmaceuticaltheranostictheranostic center

More Related Videos

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.3K
Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.4K

Related Experiment Videos

Last Updated: Jun 28, 2025

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

11.3K
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.3K
Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.4K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical science

Background:

  • Renewed clinical interest in radiopharmaceuticals for cancer treatment (curative/palliative).
  • Stakeholders (radiation oncologists, radiopharmacists, physicians) are adapting trial designs and facilities.
  • Radiopharmaceuticals are now viewed as drugs, distinct from beam radiotherapy, facilitating study.

Purpose of the Study:

  • To highlight the clinical advancement and study of targeted radiopharmaceuticals.
  • To describe the necessary reforms in trial efforts and facilities.
  • To explain the impact of radiopharmaceuticals on clinical trial enterprise and patient experience.

Main Methods:

  • Facilitating radiopharmaceutical studies within traditional clinical trial phases (0-I to III).
  • Reforming trial efforts and remodeling facilities for radioactive investigational drug products.
  • Leveraging theranostic agents (diagnostic and therapeutic radionuclide pairs).

Main Results:

  • Easier study of radiopharmaceuticals in conventional clinical trials.
  • Development of new logistics and improved patient experience for safe drug delivery.
  • Accelerated radiopharmaceutical development driven by theranostic agents.

Conclusions:

  • Radiopharmaceuticals represent a significant advancement in cancer therapy.
  • The integration of theranostics is key to future radiopharmaceutical innovation.
  • Adaptation of infrastructure and trial methodologies supports radiopharmaceutical progress.